Hong Jian

2.3k total citations
50 papers, 978 citations indexed

About

Hong Jian is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hong Jian has authored 50 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Hong Jian's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Hong Jian is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Hong Jian collaborates with scholars based in China, United States and Hong Kong. Hong Jian's co-authors include Shun Lü, Bin Liu, Ying C. Q. Zang, Yi Zhao, Debasis Das, Jingwu Z. Zhang, Víctor M. Rivera, Yaping He, Jingfen Zhu and Guohong Li and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Virology.

In The Last Decade

Hong Jian

46 papers receiving 948 citations

Peers

Hong Jian

ONCOL

PRM

EPIDE

Kent Armeson United States

Helen Morris United Kingdom

Albert M. Bernath United States

Corey Pelletier United States

Christian Kersten Norway

Loredana Santo United States

Toby N. Trahair Australia

Péter Nyírády Hungary

Elizabeth R. Kessler United States

Kent Armeson United States

Hong Jian

483 ×1.2

ONCOL

391 ×1.1

PRM

491 ×1.6

151 ×1.2

117 ×1.3

EPIDE

Citations per year, relative to Hong Jian Hong Jian (= 1×) peers Kent Armeson

Countries citing papers authored by Hong Jian

Since Specialization

Citations

This map shows the geographic impact of Hong Jian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Jian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Jian more than expected).

Fields of papers citing papers by Hong Jian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong Jian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Jian. The network helps show where Hong Jian may publish in the future.

Co-authorship network of co-authors of Hong Jian

This figure shows the co-authorship network connecting the top 25 collaborators of Hong Jian. A scholar is included among the top collaborators of Hong Jian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong Jian. Hong Jian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jian, Hong, Min Ruan, Zhangbiao Long, et al.. (2025). Low-dose ATG/PTCy for graft-versus-host disease prevention in haploidentical transplantation: a single-center experience. Frontiers in Oncology. 15. 1569149–1569149.

Das, Debasis, et al.. (2024). Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024). RSC Medicinal Chemistry. 15(10). 3371–3394. 24 indexed citations

Jian, Hong, et al.. (2024). Efficacy and safety of hetrombopag in the treatment of recombinant human thrombopoietin–resistant thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Research and Practice in Thrombosis and Haemostasis. 8(7). 102578–102578. 1 indexed citations

Lü, Shun, Chuan Li, Hong Jian, et al.. (2023). Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS. Cancer Research. 83(7_Supplement). 5462–5462. 1 indexed citations

Chen, Jieling, Jingfen Zhu, Hong Jian, et al.. (2022). Typology of Family Relationships, Psychological Distress, and Quality of Life in Chinese Patients With Advanced Lung Cancer. Cancer Nursing. 45(3). E655–E662. 6 indexed citations

Lü, Shun, Xiaorong Dong, Hong Jian, et al.. (2021). Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).. Journal of Clinical Oncology. 39(15_suppl). 9013–9013. 22 indexed citations

Lü, Shun, Jianying Zhou, Xiaomin Niu, et al.. (2021). Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Translational Lung Cancer Research. 10(2). 839–854. 8 indexed citations

Das, Debasis & Hong Jian. (2020). Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer. Current Enzyme Inhibition. 16(1). 4–19. 6 indexed citations

Das, Debasis, et al.. (2020). In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Bioorganic Chemistry. 99. 103790–103790. 22 indexed citations

10.

He, Yaping, Hong Jian, Jingfen Zhu, et al.. (2019). Coping, mood and health-related quality of life: a cross-sectional study in Chinese patients with advanced lung cancer. BMJ Open. 9(5). e023672–e023672. 20 indexed citations

11.

Das, Debasis, et al.. (2019). Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. Bioorganic & Medicinal Chemistry Letters. 29(12). 1514–1517. 10 indexed citations

12.

Lou, VW, Hong Jian, Zhen Zhou, et al.. (2017). Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients. Supportive Care in Cancer. 26(4). 1265–1272. 60 indexed citations

13.

Jian, Hong, Wěi Li, Zhiyong Ma, et al.. (2017). Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Scientific Reports. 7(1). 8483–8483. 6 indexed citations

14.

Shen, Lan, Xiaomin Niu, Hong Jian, et al.. (2017). Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. Lung Cancer. 111. 43–50. 2 indexed citations

15.

Yu, Yinghua, Hong Jian, Lisong Shen, Lei Zhu, & Shun Lü. (2016). Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases. European Journal of Surgical Oncology. 42(11). 1714–1719. 44 indexed citations

16.

Jian, Hong, Yi Zhao, Bin Liu, & Shun Lü. (2015). SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo. Cellular Signalling. 27(6). 1208–1213. 48 indexed citations

17.

Jian, Hong, Bin Liu, & Jie Zhang. (2014). Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion. Tumor Biology. 35(5). 4949–4955. 22 indexed citations

18.

Jian, Hong, Yi Zhao, Bin Liu, & Shun Lü. (2014). SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer. Tumor Biology. 35(11). 11051–11056. 59 indexed citations

19.

Zhang, Li, Xue Hou, Shun Lü, et al.. (2009). Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study. Lung Cancer. 67(1). 114–119. 36 indexed citations

20.

Sun, Wenjing, et al.. (2006). Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. International Immunology. 18(12). 1691–1700. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact